Single Patient Expanded Access Protocol: Metabolic Boost

NO_LONGER_AVAILABLE

Conditions studied: Metachromatic Leukodystrophy

In brief

This is a single patient expanded access protocol to investigate the effects of a second dose of facilitating cell-enhanced hematopoietic stem cell product.

Key facts

Study ID

NCT02021266

Run by

Talaris Therapeutics Inc.

Last updated by the study team

2020-10-08

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Subject was previously enrolled and qualified for transplant under IND 14070. Subject must be free from infection and have normal liver, kidney, heart and pulmonary function to proceed to a second transplant.
• Patient must have adequate function of other organ systems as measured by:
• Creatinine < 2.0 mg/dl and creatinine clearance ≥60 cc/min/1.73m2. Newborns must have a creatinine clearance > 25 cc/min. For babies < 3 months of age, the raw value on GFR must be > 1 cc/kg/min.
• Hepatic transaminases (ALT/AST) 2.5 x normal, bilirubin <2.0mg/dl
• Normal cardiac function by echocardiogram or radionuclide scan (ejection fraction or shortening fraction >80% of normal value for age)
• Pulmonary function tests (PFT) demonstrating forced expiratory volume at one second (FEV1) of >50% of predicted for age. If child is too young or unable to perform PFTs, crying vital capacity result of >50% of normal value for age or resting pulse oximeter >92% on room air or clearance by pulmonologist will be required.
• Patient, and parent, or legal guardian must have given written informed consent according to FDA guidelines.
• Patient must have a minimum life expectancy of at least 6 months.
• Female patients of childbearing potential cannot be pregnant or lactating/breast-feeding and must be either surgically sterile, postmenopausal (no menses for the previous 12 months), or must be practicing an effective method of birth control as determined by the investigator (e.g., oral contraceptives, double barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or partner with vasectomy).
• Recipient screening to include glomerular filtration rate (GFR), chest X-ray (CXR), hepatic and renal chemistries, coagulation studies, pulmonary function testing, and ECHO if clinically relevant, chimerism testing, type and screen, and enzyme levels within 30 days of retransplant.

You may not qualify if…

• Uncontrolled seizures, apnea, evidence of recurrent or uncontrolled aspiration, or need for chronic mechanical ventilation.
• Subject must not have had previous radiation therapy that would preclude total body irradiation (TBI) (as determined by radiation therapist)
• Uncontrolled infection or severe concomitant diseases, which in the judgment of the Principal Investigator, could not tolerate reduced intensity transplantation.
• Subject with a positive human immunodeficiency virus (HIV) antibody test result
• Subject who are pregnant, as indicated by a positive serum human chorionic gonadotropin (HCG) test
• Subject whose only donor is pregnant at the time of intended transplant
• Subject of childbearing potential who are not practicing adequate contraception as defined by the investigator at the site
• Jehovah's witnesses being unwilling to be transfused
• Patient that have any comorbid condition which, in the view of the Principal Investigators, renders the patient at too high a risk from treatment complications and regimen related morbidity/mortality.
• Insufficient funds for bone marrow processing.

Where it is running

• Duke University — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.